Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution.
about
CD146(+) bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosisPhase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.One thousand patients with primary myelofibrosis: the mayo clinic experience.Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review.Allogeneic hematopoietic cell transplantation for patients with myelofibrosisTherapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosisBCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques.Myeloproliferative neoplasms: Morphology and clinical practice.Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis.Usefulness of spleen volume measured by computed tomography for predicting clinical outcome in primary myelofibrosis.Very poor outcome of leukemic transformation in myelofibrosis: a single center experience with 13 patients.Application of five prognostic survival scores to primary myelofibrosis in 62 Brazilian patients.Prognostication in primary myelofibrosis.Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms.Prognosis: A variable parameter. Dynamic prognostic modeling in head and neck squamous cell carcinoma
P2860
Q24649607-C8ECB188-FEFD-4CA5-BAE3-66FDF3C7D60EQ33387514-15A2B920-B3CE-46A9-8819-AED11AEB5D0FQ33392291-3FBB393C-9555-4B6F-B02E-7F3EA1E59FD0Q33403735-5A50F04D-A6B4-480B-ADAC-51817E24F79BQ35849342-B54077C7-BCD0-468F-86C3-2ED3B1800DE4Q36001930-55226606-CF44-4599-B6C2-F980F02CD5A6Q36512816-2495D57C-4CC9-4108-9268-13F7FFD78D62Q37481181-23D21FA5-9964-4992-9956-A1397FAD762BQ37495397-30E18BEA-01B8-4E8D-BF60-65E26B86F68FQ37705695-4D6ABCA3-8F0F-4B45-B1DB-5A6C06A4C281Q38014534-5D46EB05-8D02-47FB-ACF6-620DBA205293Q38683559-9D2629C9-D5C8-461F-83DF-FA72B4F1B149Q39255427-B16287D7-7382-4D73-BE4D-271CA695FD64Q40679370-908993B5-806F-43D1-A8D1-B9C46587A5C0Q44107175-5BC41985-C893-4638-AD61-9FBC02EB3D85Q44300500-B6939FD1-B49B-4626-BBDB-D00DA7B990E3Q44731549-6C54111C-9F90-40AA-93E9-565E725B18E0Q53136705-9EC54FAD-61D5-46A9-8E04-2F5F101DC180Q55399862-6DDDDA75-6818-4A05-8652-038C687DC831Q57259800-7818F046-7023-4C09-BA19-08FABC8F7E69
P2860
Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Validation and comparison of c ...... nts from a single institution.
@ast
Validation and comparison of c ...... nts from a single institution.
@en
type
label
Validation and comparison of c ...... nts from a single institution.
@ast
Validation and comparison of c ...... nts from a single institution.
@en
prefLabel
Validation and comparison of c ...... nts from a single institution.
@ast
Validation and comparison of c ...... nts from a single institution.
@en
P2093
P356
P1433
P1476
Validation and comparison of c ...... nts from a single institution.
@en
P2093
Animesh Pardanani
Chin-Yang Li
Jocelin Huang
Ruben A Mesa
Susan Schwager
Wenting Wu
P304
P356
10.1002/CNCR.22630
P407
P577
2007-05-01T00:00:00Z